Patrick Langlois

Chairman


Patrick Langlois has 30 years of international experience in health companies and health sector markets. His career began at the Louis Dreyfus Bank as an “Equity Research Analyst”. From January 1975 to December 1999 he held various posts in the Rhône-Poulenc Group, including Finance Director. From January 2000 to the end of 2004, Mr. Langlois worked at Aventis SA as Group Executive Vice President, Financial Director, and then in May 2002, Vice President Director. He has also been Senior Advisor to JP Morgan (2007-2008) and Rothschild (2005-2006).

Since 2005, Mr. Langlois he has been Associate Manager for PJL Conseils Eurl, a specialist strategic advisory company in Paris specializing in enterprise development and M&A activities for health sector companies.

Mr. Langlois holds a 3rd Cycle Diploma in Economics from the University of Rennes (1968) and a Higher Training Certificate in Banking (1974). He is also a board member for several pharmaceutical companies in France and overseas, including Stallergènes where he has been Chairman of the Executive Council since 2012. He is an Executive with the Scynexis Company and member of the Supervising Council for Innate Pharma and Newron Pharmaceuticals SpA.

Patrick Langlois

Dominique Costantini

Independent Director

With more than 20 years of experience in the pharmaceutical industry, Dr. Dominique Costantini has overseen many therapeutic innovations in the international framework of oncology. Throughout her career, she held a of management positions within HMR (now Sanofi) where she led medico-marketing activities to commercialize products (notably in immunology, endocrinology, infectious illnesses and oncology). While there, Ms. Costantini also participated in the development of various medicines, from conception to product approval and commercialization.

In 1997, Ms.Costantini founded BioAlliance Pharma, where she held the position of Chief Executive Officer until 2011 and during which time, she led BioAlliance Pharma’s IPO on Euronext (2005). BioAlliance Pharma originated Livatag®, an anti-cancer nanotechnology in primary liver cancer, currently in Phase 3 (in Europe and the USA). In her experience, Ms. Costantini has been the source of many international industrial partnerships (Europe, USA, China, Japan and Korea). To date, BioAlliance Pharma (renamed Onxeo in 2014) is the only French biotechnology company to have two FDA drug approvals.
In 2012, Ms. Costantini co-founded and led OSE Pharma as Chief Executive Officer.

Dr. Dominique Costantini is a doctor (Paris V university), who specializes in immunology.

 

 Dominique Costantini 1030x1030

Eric de la Fortelle

Independent Director

Dr. Forquenot de la Fortelle is a graduate of the Ecole Centrale de Paris, and holds the DEA (Higher Training Diploma) from Paris VI Pierre et Marie Curie, a doctorate from Paris XI Orsay and an MBA from INSEAD. He began his professional career as an academic researcher in life sciences involved in the discovery of many new medications, such as synchrotron LURE, Orsay and MRC-LMB, Cambridge) and later worked in biotech companies, including Structural GenomiX, Inc. in San Diego, CA and Hoffmann-La Roche in Basel. Subsequently, he was CEO of Delenex Therapeutics AG (Zurich) before returning to Seventure Partners on 1st January 2014 as a Venture Partner.

Eric Fortelle

Chahra Louafi

Permanent Representative of BPI investment

Mrs. Louafi is responsible for developing and implementing projects and creating companies within Mendel Partner, a private company incubator specializing in biotechnologies. She joined CDC Enterprises in 2001 as Investment Director, where she was responsible, amongst other things, for investment and biotechnology funds, particularly launch funds, and for technology transfer operations. In October 2009 Ms. Louafi joined the management team for InnoBio funds, a fund run by CDC Enterprises dedicated to biotechnology companies. She is also Chairman of the Inserm Initiative Transfer Monitoring Commission and a Member of Cap Décisif Management Committee.

Mrs. Louafi is a graduate of the Paris-Dauphine University (Masters Degree in Management Technology and Innovation), of the Paris X Nanterre University (Masters Degree in Company Finance), and of the National Agronomics Institute of Paris-Grignon (Masters Degree in Microbiology and Enzyme Engineering). She is also in on the Boards of DBV Technologies, Sensorion, Eyevensys, MedDay, Pixium Vision and Lysogène.

Chahra Louafi

Jean-François Morin

Director

A graduate of EDHEC, Mr. Morin began his career in 2005 at MAZARS as a Financial Auditor.  In 2009 he joined CDC Enterprises, an InnoBio Funds Management company, as Financial Manager where he was involved in structuring several investment funds and value creation from participations, mostly in venture capital.  In September 2013, Mr. Morin joined the Laurent Arthaud team in InnoBio Funds as Head of Investment.

Jean Francois Morin

Nawal Ouzren

CEO of Sensorion

With fifteen years of experience in operational and strategic management within the pharmaceutical industry, Nawal Ouzren started out at Baxter, where she was Strategy and Operational Excellence Manager, Quality Operations Director and Senior Director Strategy before becoming Vice President of the BioSimilaires business unit. In 2014, she became Vice President of the Global Hemophilia Franchise at Baxalta, which had been incorporated within the Shire group. In 2016, she took control of the Shire group’s Global Genetic Diseases division, where she supervised all marketing, business and strategy aspects of this global division’s product portfolio.

NO borad of director

François Thomas

Permanent Representative of INSERM Transfert Initiative

As an oncology physician and former clinical Senior Registrar at the Gustave Roussey Institute, with an MBA from the Massachusetts Institute of Technology, Dr. Thomas is Director General of the Inserm Transfer Initiative (ITI) Funds. In addition to his medical experience, his multi-disciplinary experience has led him to positions of Clinical Development Director for the Ipsen Company, Management Associate for Bioserve Ltd Consulting Company, Director of Licenses and Medical Affairs for Genset, and the Chariman of Cynthéris. He has also been involved in the Atlas Venture Investment Funds and is Head of Corporate Financial Activities for Health at Bryan Garnier. In the last 15 years, he has been dedicated mostly to creating and developing biotechnology companies in Europe.

Francois Thomas
   
   

 

Enregistrer

Pipeline

pipeline2017

Enregistrer

Corporate presentation